Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your morning coffee might affect your eye health – new study investigates

NCT ID NCT03675412

Knowledge-focused Sponsor: Wills Eye Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study looks at how caffeine changes blood flow in the back of the eye in people with glaucoma and in healthy volunteers. Researchers will use a special camera to measure blood flow before and after drinking caffeine. The goal is to understand if caffeine affects eye health differently in glaucoma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2018

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18 to 90 years * diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced) * healthy subjects with no eye disease Exclusion Criteria: * Diseases, ophthalmic or systemic, that are likely to affect OCTA results * greater than moderate cataract * nystagmus * inability to look at target * macular degeneration other than mild drusen or pigmentary changes * diabetic retinopathy * neovascular glaucoma or non-glaucoma optic neuropathies * current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy * keratoconus, corneal ectasia, central corneal scarring * rheumatologic diseases or Raynaud's phenomena * pregnant and lactating women * mental illness or alcohol addiction * pre-existing bladder symptoms, cardiac disease or sleep disorder * refractive spherical diopter greater than 5 or cylinder greater than 3 * possible tolerance to caffeine (drinking more than 1 cup coffee per day).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma, primary open angle are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma, primary open angle

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Wills Eye Glaucoma Service

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.